AMRX•benzinga•
Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars
Summary
Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 28, 2025 by benzinga